JORDEN DAVID EMERSON (CEO, CFO) sold 7.6% of their position (162.50K shares) of NUO THERAPEUTICS, INC. on the open market
Open‑market sale worth $243.8K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−30K
Price / share
$1.50
Trade value
$45K
% of position
Common Stock
Shares
−30K
Price / share
$1.50
Trade value
$45K
% of position
Common Stock
Shares
−27K
Price / share
$1.50
Trade value
$40.50K
% of position
Common Stock
Shares
−20K
Price / share
$1.50
Trade value
$30K
% of position
Common Stock
Shares
−20K
Price / share
$1.50
Trade value
$30K
% of position
Common Stock
Shares
−13.50K
Price / share
$1.50
Trade value
$20.25K
% of position
Common Stock
Shares
−10K
Price / share
$1.50
Trade value
$15K
% of position
Common Stock
Shares
−7K
Price / share
$1.50
Trade value
$10.50K
% of position
Common Stock
Shares
−5K
Price / share
$1.50
Trade value
$7.50K
% of position
Net shares
−162.50K
Net value
-$243.75K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/9/2022 | S · Sale | −30K | $1.50 | $45K | 1.4% | 2.14M | 2.11M |
| Common Stock Direct | 11/9/2022 | S · Sale | −30K | $1.50 | $45K | 1.4% | 2.11M | 2.08M |
| Common Stock Direct | 11/9/2022 | S · Sale | −27K | $1.50 | $40.50K | 1.3% | 2.08M | 2.05M |
| Common Stock Direct | 11/9/2022 | S · Sale | −20K | $1.50 | $30K | 1.0% | 2.05M | 2.03M |
| Common Stock Direct | 11/9/2022 | S · Sale | −20K | $1.50 | $30K | 1.0% | 2.03M | 2.01M |
| Common Stock Direct | 11/9/2022 | S · Sale | −13.50K | $1.50 | $20.25K | 0.7% | 2.01M | 2M |
| Common Stock Direct | 11/9/2022 | S · Sale | −10K | $1.50 | $15K | 0.5% | 2M | 1.99M |
| Common Stock Direct | 11/9/2022 | S · Sale | −7K | $1.50 | $10.50K | 0.4% | 1.99M | 1.98M |
| Common Stock Direct | 11/9/2022 | S · Sale | −5K | $1.50 | $7.50K | 0.3% | 1.98M | 1.98M |
| Total | −162.50K | -$243.75K | ||||||